Hyundai Bio Prepares Large-Scale Facilities for Global Supply of COVID-19 Treatment... "Patent Applications Filed for Core Technology in Key Countries"

[Asia Economy Reporter Hyungsoo Park] Hyundai Bio is accelerating its efforts to apply for emergency use authorization from health authorities for its broad-spectrum antiviral candidate CP-COV03 as a COVID-19 treatment.

Hyundai Bio announced on the 22nd that it has completed ordering 15 dedicated manufacturing facilities from domestic company H to produce 200,000 doses per month of CP-COV03 as a COVID-19 treatment (brand name Zepti), and some of the equipment has already been delivered and is being assembled. Hyundai Bio plans to complete the establishment of all production facilities for CP-COV03 contract manufacturing companies by the end of October.

A Hyundai Bio official stated, "To apply for emergency use authorization for CP-COV03 as a COVID-19 treatment, a mass production system must be established in advance. We initially ordered production facilities to produce 200,000 doses per month to supply CP-COV03 worldwide, and depending on the situation, we can increase the production facilities further."

Hyundai Bio is also smoothly securing the main raw materials such as niclosamide and magnesium oxide (MgO) to support the smooth mass production of CP-COV03. The company has completed purchasing 4 tons of magnesium oxide, equivalent to 840,000 doses per month, from overseas, which requires stable prior procurement. Niclosamide procurement sources have already been secured domestically with pharmaceutical company D and internationally with Spanish pharmaceutical company O.

To protect the intellectual property rights related to CP-COV03, Hyundai Bio has filed patents for the fundamental technology, including the manufacturing principles and processes of this drug with niclosamide as the main ingredient, in major advanced countries such as the United States, Europe, and Japan, as well as across all continents including Africa, South America, Southeast Asia, and the Middle East.

When domestic companies file overseas patents, they typically target around 10 countries, mainly advanced countries or those with large populations such as the United States, Europe, Japan, China, India, Russia, and Australia. Hyundai Bio has extended its patents to countries in Africa, Latin America, Southeast Asia, and the Middle East, including South Africa, Brazil, Mexico, Vietnam, Thailand, and Israel.

A Hyundai Bio official explained, "CP-COV03 is a platform-type antiviral with various pipelines effective against multiple viral infectious diseases such as dengue fever and HPV, which causes cervical cancer, in addition to COVID-19. To protect all intellectual property rights related to CP-COV03's broad-spectrum nature, we have expanded overseas patents to major countries across all continents."

To accelerate the clinical trials of CP-COV03 for COVID-19, Hyundai Bio plans to conduct sequential clinical trials at major university hospitals nationwide, including Kyungpook National University School of Medicine’s main hospital and Chilgok Hospital, Korea University Anam Hospital, and Keimyung University Dongsan Hospital, which are registered as cooperating institutions with the National Clinical Trial Support Foundation.

The Phase 2 clinical trial of CP-COV03 for COVID-19 is progressing smoothly. As of the 21st, the cumulative number of patients participating in the trial reached 112, approaching half of the target enrollment of 300.

This content was produced with the assistance of AI translation services.